Healing & Recovery Protocol
VIP (Vasoactive Intestinal Peptide)Complete Dosing & Administration Guide
Endogenous neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties
Dose Range
67 mcg/day-300 mcg/daymcg
Frequency
Once daily
Route
Intravenous infusion
Cycle Length
Ongoing/indefinite
Dosing
How much
do I take?
Timing
Best time to take
VIP (Vasoactive Intestinal Peptide) is administered intravenously in a clinical setting. Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.
With food?
IV administration of VIP (Vasoactive Intestinal Peptide) is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.
If stacking
VIP (Vasoactive Intestinal Peptide) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Administration
How do I
use it?
Reconstitution
What you need
- •VIP (Vasoactive Intestinal Peptide) vial (lyophilized powder or solution)
- •Bacteriostatic water or sterile sodium chloride for reconstitution
- •Alcohol swabs for cleaning vial tops and injection sites
- •Appropriately sized syringes with fine-gauge needles (27-30 gauge)
- •Sharps disposal container
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- •Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- •Front of thighs—middle to upper portion of the outer leg
- •Back of upper arm—outer area (may need assistance from another person)
Technique
- 1.Wash your hands thoroughly with soap and water before handling supplies
- 2.Clean the injection site with an alcohol swab and let it air dry completely
- 3.Pinch a fold of skin at the chosen injection site
- 4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 5.Inject the medication slowly and steadily over 5-10 seconds
- 6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 7.Rotate injection sites to prevent tissue irritation or lipodystrophy
- 8.Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
VIP (Vasoactive Intestinal Peptide) is a 28-amino acid endogenous neuropeptide with moderate evidence from Phase 1-2 human clinical trials. The synthetic pharmaceutical form (aviptadil/RLF-100) received FDA fast-track designation for COVID-19-associated ARDS, indicating recognition of its therapeutic potential. Critical safety considerations: VIP is a potent vasodilator that causes dose-dependent hypotension and compensatory tachycardia—hemodynamic monitoring is essential during IV administration. Common side effects include facial flushing and diarrhea from its GI effects. Phase 2b/3 COVID-19 ARDS trials (196 patients) reported NO serious drug-related adverse events, a favorable safety signal. However, individual responses to vasodilation vary significantly based on baseline cardiovascular status, medications, and underlying conditions. The peptide's short plasma half-life (1-2 minutes) limits systemic accumulation. Inhaled VIP shows excellent local tolerability for pulmonary applications with minimal systemic absorption.
VIP's therapeutic evidence comes from Phase 1-2 human clinical trials in pulmonary conditions and a Phase 2b/3 COVID-19 ARDS trial (NCT04703816) that showed improved 60-day survival rates. As an endogenous 28-amino-acid neuropeptide, its pharmacology is well-characterized from decades of basic science research. Clinical applications require IV infusion with continuous hemodynamic monitoring.
Common Side Effects
Experienced by some users
Facial Flushing
Common cutaneous vasodilation causing temporary redness of face and trunk during systemic administration
Management: Transient and self-resolving; no treatment typically required
Diarrhea
Gastrointestinal smooth muscle effects and secretory stimulation may cause watery diarrhea, especially with systemic administration
Management: Usually transient; anti-diarrheal agents if needed; dose adjustment may help
Nausea
Gastrointestinal effects including nausea and occasional vomiting during or shortly after systemic administration
Management: Antiemetic medications as needed; typically improves with continued therapy
Less Common
- •Hypotension
- •Tachycardia
- •Cardiovascular Effects
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with VIP (Vasoactive Intestinal Peptide)
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
VIP (Vasoactive Intestinal Peptide) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓Complementary vasodilatory pathways may enhance pulmonary hemodynamic improvement in pulmonary hypertension
- ✓Combining with other anti-inflammatory agents like KPV may provide synergistic cytokine suppression
- ✓VPAC receptor-mediated neuroprotection complements other neuroprotective strategies in neurodegeneration research
With medications
- !Antihypertensive Medications - Additive hypotensive effects may cause dangerous blood pressure drops requiring careful hemodynamic monitoring
- !PDE5 Inhibitors - Combined vasodilation through different mechanisms may cause severe hypotension
- !Vasoconstrictors - Pharmacological antagonism with VIP vasodilatory effects may reduce therapeutic efficacy of both agents
With supplements
- ✓Multivitamins - Generally safe to take alongside VIP (Vasoactive Intestinal Peptide). Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Want the Full Picture?
View the complete VIP (Vasoactive Intestinal Peptide) research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.
View Full VIP (Vasoactive Intestinal Peptide) Profile